BrainCheck, a digital platform for cognitive assessment and care, today announced that it has raised an additional $13 million in Series A financing. The round was led by Next Coast Ventures, with participation from S3 Ventures and UPMC Enterprises.
The funding will support the expansion of BrainCheck’s enterprise cognitive care infrastructure, including deeper workflow integration, longitudinal patient monitoring, population-scale deployment across primary care and specialty settings, and advanced AI-assisted clinical infrastructure designed for risk-bearing and value-based environments.
Read More – Rebound Technologies Raises in Funding
In addition to technology expansion, BrainCheck is now partnering with collaborative care organizations to operationalize cognitive care delivery within practices that lack the staffing or infrastructure to execute comprehensive care workflows. These partnerships extend BrainCheck beyond assessment into structured, scalable cognitive care pathways—supporting providers with both digital tools and operational care enablement models.
As populations age and accountability for cognitive outcomes shifts toward value-based and risk-bearing models, standardized cognitive assessment is increasingly serving as the entry point to new care pathways. BrainCheck’s platform is designed to help practices identify cognitive impairment earlier and activate structured follow-up care in a sustainable, scalable manner.
“Cognitive health is becoming a greater priority across the healthcare system, and the infrastructure supporting it must evolve as well,” said Mike Smerklo, Co-Founder and Managing Partner of Next Coast Ventures. “BrainCheck is contributing to that evolution by bringing greater consistency, objectivity, and longitudinal insight into cognitive care. We’re excited to support the company’s next phase of growth.”
“UPMC clinicians have been evaluating BrainCheck for several years and have seen firsthand how standardized digital cognitive assessment can support them in real-world practice,” said Adele Towers, M.D., M.P.H., UPMC geriatrician and senior clinical advisor to UPMC Enterprises, the innovation, commercialization, and venture capital arm of UPMC. “We look forward to our continued engagement with BrainCheck and bringing it to more clinicians supporting patients who could benefit from earlier detection, long-term monitoring, and scalable cognitive care within and beyond our health system.”
BrainCheck is used by more than 500 healthcare organizations nationwide, with clinicians having completed over 640,000 cognitive assessments using BrainCheck Assess™, the company’s FDA Class II digital cognitive assessment (DCA). The BrainCheck platform offers 29 validated cognitive screeners and care planning tools designed to enable standardized, repeatable measurement and longitudinal tracking, fully integrated into clinical workflows.
Testing protocols are customizable within the BrainCheck platform and available in English and Spanish. Providers across primary care, neurology, and psychiatry use the platform to assess and monitor cognitive function and behavioral changes across a range of neurological and psychiatric conditions, with a primary focus on mild cognitive impairment (MCI) and dementia-related diseases, including Alzheimer’s disease.
Read More – Encord Raises $60M in Series C Funding
